Last reviewed · How we verify

SABER-Bupivacaine Treatment 1a

Durect · Phase 2 active Small molecule

SABER-Bupivacaine Treatment 1a is a Small molecule drug developed by Durect. It is currently in Phase 2 development. Also known as: POSIMIR® bupivacaine solution.

At a glance

Generic nameSABER-Bupivacaine Treatment 1a
Also known asPOSIMIR® bupivacaine solution
SponsorDurect
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about SABER-Bupivacaine Treatment 1a

What is SABER-Bupivacaine Treatment 1a?

SABER-Bupivacaine Treatment 1a is a Small molecule drug developed by Durect.

Who makes SABER-Bupivacaine Treatment 1a?

SABER-Bupivacaine Treatment 1a is developed by Durect (see full Durect pipeline at /company/durect).

Is SABER-Bupivacaine Treatment 1a also known as anything else?

SABER-Bupivacaine Treatment 1a is also known as POSIMIR® bupivacaine solution.

What development phase is SABER-Bupivacaine Treatment 1a in?

SABER-Bupivacaine Treatment 1a is in Phase 2.

Related